20.49
1.21%
-0.25
After Hours:
20.49
Syndax Pharmaceuticals Inc stock is currently priced at $20.49, with a 24-hour trading volume of 1.21M.
It has seen a -1.21% decreased in the last 24 hours and a -6.52% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $20.96 pivot point. If it approaches the $20.37 support level, significant changes may occur.
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Syndax Pharmaceuticals Inc (SNDX) Revenue 2024
SNDX reported a revenue (TTM) of $139.71 million for the quarter ending December 31, 2021.
Syndax Pharmaceuticals Inc (SNDX) Net Income 2024
SNDX net income (TTM) was -$209.36 million for the quarter ending December 31, 2023, a -40.19% decrease year-over-year.
Syndax Pharmaceuticals Inc (SNDX) Cash Flow 2024
SNDX recorded a free cash flow (TTM) of -$160.60 million for the quarter ending December 31, 2023, a -20.14% decrease year-over-year.
Syndax Pharmaceuticals Inc (SNDX) Earnings per Share 2024
SNDX earnings per share (TTM) was -$2.96 for the quarter ending December 31, 2023, a -20.82% decline year-over-year.
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Cap:
|
Volume (24h):